DiaSorin S.p.A. (DSRLF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, DiaSorin S.p.A. (DSRLF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 52/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026DiaSorin S.p.A. (DSRLF) Resumen de Asistencia Médica y Tuberías
DiaSorin S.p.A., founded in 1968, is a global leader in immunodiagnostics and molecular diagnostics, offering a broad portfolio of testing kits and platforms. With a focus on infectious diseases and specialty diagnostics, DiaSorin serves diverse markets across Europe, the Americas, Asia Pacific, and China, maintaining a strong competitive position through strategic partnerships and innovative solutions.
Tesis de Inversión
DiaSorin S.p.A. presents a notable research candidate within the diagnostics sector, supported by its strong market position, diversified product portfolio, and global reach. The company's focus on specialty diagnostics and infectious disease testing positions it favorably to capitalize on growing demand for advanced diagnostic solutions. With a P/E ratio of 18.19 and a profit margin of 15.8%, DiaSorin demonstrates solid profitability. Key growth catalysts include the expansion of its LIAISON platform, strategic partnerships, and entry into new geographic markets. However, investors may want to evaluate potential risks such as competition, regulatory changes, and fluctuations in currency exchange rates. The company's beta of 0.62 suggests lower volatility compared to the overall market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $4.38 billion, reflecting its significant presence in the diagnostics market.
- P/E ratio of 18.19, indicating a potentially reasonable valuation relative to its earnings.
- Profit margin of 15.8%, demonstrating efficient operations and profitability.
- Gross margin of 65.7%, showcasing the company's ability to maintain strong pricing power and cost control.
- Dividend yield of 1.86%, providing a steady income stream for investors.
Competidores y Pares
Fortalezas
- Strong market position in immunodiagnostics and molecular diagnostics.
- Diversified product portfolio with a broad range of diagnostic tests.
- Global presence with direct operations in key markets.
- Proprietary LIAISON technology platform.
Debilidades
- Reliance on a limited number of key products.
- Exposure to regulatory risks and changes in healthcare policies.
- Competition from larger, more diversified players.
- Dependence on third-party suppliers for certain raw materials and components.
Catalizadores
- Upcoming: Launch of new diagnostic tests for emerging infectious diseases in Q3 2026.
- Ongoing: Expansion of the LIAISON platform with new assays for autoimmune disorders.
- Ongoing: Strategic partnerships to expand product portfolio and geographic reach.
- Ongoing: Geographic expansion into emerging markets in Asia Pacific and Latin America.
Riesgos
- Potential: Intense competition from established players and new entrants in the diagnostics market.
- Potential: Price pressures from healthcare providers and payers.
- Potential: Technological obsolescence and the need for continuous innovation.
- Ongoing: Regulatory risks and changes in healthcare policies.
- Ongoing: Dependence on third-party suppliers for certain raw materials and components.
Oportunidades de crecimiento
- Expansion of LIAISON Platform: DiaSorin can further expand its LIAISON platform by developing and launching new assays for emerging infectious diseases and specialty diagnostic areas. This includes assays for autoimmune disorders, bone and mineral metabolism, and gastrointestinal diseases. The global market for autoimmune disease diagnostics is projected to reach $12.7 billion by 2027, presenting a significant opportunity for DiaSorin to capture market share. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: DiaSorin can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborations with companies specializing in molecular diagnostics, point-of-care testing, or digital health solutions can enhance DiaSorin's competitive position and accelerate its growth. The company's existing partnerships with QIAGEN, TTP, and MeMed demonstrate its commitment to strategic collaborations. Timeline: Ongoing.
- Geographic Expansion: DiaSorin has opportunities to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where demand for diagnostic testing is growing rapidly. Establishing local manufacturing facilities, distribution networks, and sales teams in these regions can enable DiaSorin to better serve local customers and capitalize on growth opportunities. The Asia Pacific IVD market is projected to be the fastest-growing region, driven by increasing healthcare expenditure and rising awareness of diagnostic testing. Timeline: 2026-2028.
- Development of Point-of-Care Testing Solutions: DiaSorin can invest in the development of point-of-care testing (POCT) solutions that enable rapid and convenient diagnostic testing at the point of care, such as in physician's offices, emergency rooms, and pharmacies. POCT solutions can improve patient outcomes by enabling faster diagnosis and treatment decisions. The global POCT market is projected to reach $40 billion by 2028, driven by increasing demand for decentralized testing and technological advancements. Timeline: 2027-2030.
- Digital Health Integration: DiaSorin can integrate its diagnostic solutions with digital health platforms and data analytics tools to provide clinicians with comprehensive insights and decision support. This includes developing mobile apps, cloud-based platforms, and data analytics algorithms that can analyze patient data, identify trends, and personalize treatment plans. The integration of digital health technologies can improve patient engagement, enhance clinical efficiency, and drive better healthcare outcomes. Timeline: 2028-2030.
Oportunidades
- Expansion into emerging markets with high growth potential.
- Development of new diagnostic tests for emerging infectious diseases.
- Strategic partnerships and acquisitions to expand product portfolio and geographic reach.
- Integration of digital health technologies to enhance diagnostic solutions.
Amenazas
- Intense competition from established players and new entrants.
- Price pressures from healthcare providers and payers.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns and their impact on healthcare spending.
Ventajas competitivas
- Proprietary LIAISON technology platform.
- Extensive portfolio of diagnostic tests.
- Global distribution network.
- Strong brand reputation in the diagnostics market.
Acerca de DSRLF
DiaSorin S.p.A., established in 1968 and headquartered in Saluggia, Italy, is a global biotechnology company specializing in the development, production, and distribution of in-vitro diagnostics (IVD). The company operates in the immunodiagnostics and molecular diagnostics segments, providing a wide array of testing kits and platforms used in clinical laboratories worldwide. DiaSorin's product portfolio includes the LIAISON series of immunodiagnostic platforms (LIAISON XS, LIAISON XL, and LIAISON XL LAS) and the LIAISON MDX molecular diagnostics platform. These platforms are designed for the automated analysis of biological samples to detect and quantify various analytes, aiding in the diagnosis and monitoring of diseases. The company's tests cover a range of clinical areas, including infectious diseases, bone and mineral metabolism, hepatitis, retrovirus, and autoimmune disorders. DiaSorin has expanded its global presence through strategic partnerships and acquisitions, establishing a direct presence in key markets such as Europe, North America, and Asia. The company's commitment to innovation is reflected in its ongoing research and development efforts, aimed at expanding its product offerings and improving the performance of its diagnostic solutions. DiaSorin's business model focuses on providing high-value diagnostic solutions to clinical laboratories, hospitals, and research institutions, contributing to improved patient outcomes and healthcare efficiency.
Qué hacen
- Develops and manufactures immunodiagnostic testing kits.
- Produces molecular diagnostic testing kits.
- Distributes diagnostic products globally.
- Offers LIAISON XS, LIAISON XL, and LIAISON XL LAS immunodiagnostic platforms.
- Provides the LIAISON MDX molecular diagnostics platform.
- Partners with other companies for diagnostic solutions.
Modelo de Negocio
- Develops and manufactures in-vitro diagnostic (IVD) kits and platforms.
- Sells diagnostic products to clinical laboratories, hospitals, and research institutions.
- Generates revenue through direct sales and distribution agreements.
- Invests in research and development to expand its product portfolio and improve its diagnostic solutions.
Contexto de la Industria
DiaSorin operates within the global in-vitro diagnostics (IVD) market, which is characterized by continuous innovation and increasing demand for accurate and rapid diagnostic testing. The market is driven by factors such as the aging population, rising prevalence of chronic diseases, and technological advancements in diagnostic techniques. The competitive landscape includes major players such as CNVVF (Siemens Healthineers), CNVVY (Roche Holding AG), and FLMNF (Thermo Fisher Scientific), each offering a broad range of diagnostic solutions. DiaSorin differentiates itself through its focus on specialty diagnostics and its LIAISON platform, which offers a comprehensive menu of tests on a single instrument.
Clientes Clave
- Clinical laboratories
- Hospitals
- Research institutions
- Diagnostic centers
Finanzas
Gráfico e información
Precio de la acción de DiaSorin S.p.A. (DSRLF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para DSRLF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para DSRLF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para DSRLF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de DSRLF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Carlo Rosa
Chief Executive Officer
Carlo Rosa serves as the Chief Executive Officer of DiaSorin S.p.A., bringing extensive experience in the diagnostics and healthcare industries. His career spans various leadership roles, including positions at multinational corporations focused on medical devices and biotechnology. He has a strong background in strategic planning, business development, and operational management. Mr. Rosa's expertise lies in driving growth through innovation, market expansion, and strategic partnerships. His leadership is focused on strengthening DiaSorin's position as a global leader in the diagnostics sector.
Historial: Under Carlo Rosa's leadership, DiaSorin has achieved significant milestones, including the expansion of its LIAISON platform and the successful launch of new diagnostic tests. He has overseen strategic acquisitions and partnerships that have strengthened the company's competitive position and expanded its geographic reach. His focus on innovation and operational excellence has contributed to DiaSorin's consistent financial performance and growth.
Información del mercado OTC de DSRLF
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that DiaSorin S.p.A. (DSRLF) may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet the minimum financial standards or disclosure requirements for higher tiers, potentially increasing investment risks. Investors should be aware that information availability and transparency may be limited.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited regulatory oversight and reporting requirements.
- Potential for lower liquidity and wider bid-ask spreads.
- Increased risk of price volatility and manipulation.
- Limited availability of financial information and transparency.
- Higher risk of fraud or misrepresentation.
- Verify the company's financial information and reporting practices.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or investigations against the company.
- Established business operations with a history of revenue generation.
- Presence of a qualified management team with relevant experience.
- Positive reviews or ratings from independent analysts or rating agencies.
- Compliance with applicable laws and regulations.
- Audited financial statements and transparent reporting practices.
Lo Que los Inversores Preguntan Sobre DiaSorin S.p.A. (DSRLF)
¿Cuáles son los factores clave para evaluar DSRLF?
DiaSorin S.p.A. (DSRLF) actualmente tiene una puntuación IA de 52/100, indicando puntuación moderada. Fortaleza clave: Strong market position in immunodiagnostics and molecular diagnostics.. Riesgo principal a monitorear: Potential: Intense competition from established players and new entrants in the diagnostics market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de DSRLF?
DSRLF actualmente puntúa 52/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de DSRLF?
Los precios de DSRLF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre DSRLF?
La cobertura de analistas para DSRLF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en DSRLF?
Las categorías de riesgo para DSRLF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from established players and new entrants in the diagnostics market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de DSRLF?
La relación P/E para DSRLF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está DSRLF sobrevalorada o infravalorada?
Determinar si DiaSorin S.p.A. (DSRLF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de DSRLF?
DiaSorin S.p.A. (DSRLF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending, which could provide additional insights.